TransMedics names Giovanni Cecere chief commercial officer, Matthew Forsyth general counsel
TransMedics appointed Giovanni Cecere as Chief Commercial Officer effective February 2, 2026, succeeding Tamer Khayal, who moves to Senior Vice President of International. The company also named Matthew Forsyth General Counsel effective March 9, 2026 or his later employment start date, succeeding Anil Ranganath, who will stay with the company through June 7, 2026 and then serve as a consultant until September 7, 2026. The filing lists severance-related payments to Ranganath, so these are senior executive changes shareholders may want to track.
Key points
- Giovanni Cecere named Chief Commercial Officer effective February 2, 2026, succeeding Tamer Khayal, who had held the role since January 2018
- Matthew Forsyth appointed Senior Vice President, General Counsel & Corporate Secretary, effective March 9, 2026 or his employment start date if later
- Anil Ranganath moves to a non-executive role, remains employed until June 7, 2026, then serves as a consultant until September 7, 2026 at an annualized fee of $10,000
- Ranganath's retention agreement payments include 0.75 times his highest base salary and bonus over the prior three years, up to nine months of COBRA premiums, and a pro-rated 2026 bonus
The filing
Written by AI on Nov 8, 2026, 1:49 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 04, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.